Last updated: March 7, 2026
What is the Drug with NDC 70700-0307?
NDC 70700-0307 refers to Otezla (apremilast). It is an oral phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease.
Current Market Landscape
Indications and Patient Population
- Psoriasis: Over 7 million Americans diagnosed, with about 3.2 million affected by moderate to severe cases suitable for systemic therapy (Gibson et al., 2022).
- Psoriatic Arthritis: Affecting approximately 1.5 million Americans.
- Behçet’s Disease: Rare, estimated at fewer than 100,000 cases globally, with a subset eligible for systemic PDE4 inhibitors.
Competitive Environment
Otezla competes with biologics and small molecules:
| Drug |
Class |
Indications |
2022 U.S. Sales |
Market Share (2022) |
| Otezla |
PDE4 inhibitor |
Psoriasis, psoriatic arthritis |
$650M |
20% |
| Humira (adalimumab) |
TNF-alpha biologic |
Psoriasis, psoriatic arthritis |
$4.6B |
60% |
| Stelara (ustekinumab) |
IL-12/23 biologic |
Psoriasis, psoriatic arthritis |
$2.4B |
15% |
| Cosentyx (secukinumab) |
IL-17A biologic |
Psoriasis, psoriatic arthritis |
$1.8B |
10% |
Market Dynamics
- Increasing preference for oral therapies over injectables.
- Otezla expanded indications in 2019 to include psoriatic arthritis.
- Market entry of biosimilars for biologics like Humira diminishes their market share.
- Pricing strategies and insurance coverage heavily influence access and utilization.
Price Trends and Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): Approximately $4,444 per 30-day supply (Express Scripts, 2023).
- Average List Price (ALP): Slightly higher, around $4,600–$4,700.
- Net Price: Varies by payer discounts, estimated at 20–30% below WAC.
Price Drivers
- Patent exclusivity and legal protections prevent generic entry until 2028.
- Insurance formularies favor Otezla due to oral administration and lower initial costs compared to biologics.
- Discount and rebate dynamics influence actual payer prices.
Future Price Trajectory
- Short-term: Likely stable, barring patent challenges or new generic entrants.
- Medium-term (2028-2030): Price decreases could occur with patent expiration.
- Long-term (post-2030): Entry of biosimilars or generics may reduce prices by 30-50%, similar to other small molecule drugs.
Impact of Patent Expiry
- Patent for Otezla is expected to expire in 2028.
- Biosimilar competition unlikely due to molecular differences from biologics but overall price reductions anticipated.
- Generic apremilast, if approved, may enter with a price discount of 50% or more relative to current WAC.
Revenue Forecasts
| Year |
Estimated Market Size (USD) |
Estimated Revenue for Otezla |
Notes |
| 2023 |
$3.2B (global psoriasis market) |
$650M |
Reflects market share and current price |
| 2025 |
$3.4B |
$700M |
Growth driven by expanding indications |
| 2028+ |
$2.7B (post-patent expiry) |
$350–$450M |
Price decline with generic entry |
Key Considerations for Investors and R&D Stakeholders
- Patent lifecycle management: Focus on lifecycle extension strategies, including new indications.
- Pricing negotiations: Payer discounts and rebates can significantly impact net revenue.
- Competitive threats: Watch for biosimilar and generic approvals post-2028.
- Innovative pipeline: Development of next-generation PDE4 inhibitors or combination therapies could influence future market share.
Key Takeaways
- NDC 70700-0307 (Otezla) generated $650M in U.S. sales in 2022.
- The current market favors oral therapies with stable pricing through 2027.
- Price reductions of 30-50% are likely post-patent expiry in 2028.
- Competition from biologics and biosimilars remains a critical factor in long-term revenue projections.
- Market growth may be constrained by penetration ceilings and payer formulary policies.
FAQs
1. What are the key factors influencing Otezla’s price stability?
Patent exclusivity, formulary access, and the absence of generic competition ensure current prices remain stable until patent expiry.
2. How will generic entry affect Otezla’s revenues?
Generic apremilast could reduce prices by half and lead to a significant revenue decline, depending on market uptake.
3. Are there upcoming indications that could extend Otezla’s patent protection?
Potential new indications could extend patent life if granted, but patent challenges are also possible.
4. How does the competitive landscape impact Otezla’s market share?
Biologics dominate for severe cases, but oral therapies like Otezla are gaining ground due to ease of administration.
5. What strategies could prolong Otezla's market viability?
Expanding indications, optimizing payer negotiations, and developing combination therapies can sustain sales.
References
[1] Gibson, D., et al. (2022). Psoriasis prevalence in the United States. Journal of Dermatological Treatment, 33(6), 558-565.
[2] Express Scripts. (2023). Price lists and formulary data.
[3] U.S. Food and Drug Administration. (2022). Otezla (apremilast) prescribing information.
